1
|
Siguier PLM, Planton M, Baudou E, Chaix Y, Delage A, Rafiq M, Wolfrum M, Gérard F, Jucla M, Pariente J. Can neurodevelopmental disorders influence the course of neurodegenerative diseases? A scoping review. Ageing Res Rev 2024; 99:102354. [PMID: 38857707 DOI: 10.1016/j.arr.2024.102354] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2024] [Revised: 04/30/2024] [Accepted: 05/27/2024] [Indexed: 06/12/2024]
Abstract
This scoping review aims at giving an overview of the possible influence of neurodevelopmental disorders (NDDs) on cognitive-behavioral neurodegenerative diseases (CBNDs). Based on the PRISMA-ScR checklist, it details the methods of NDDs screening, the identified NDDs-CBNDs associations, as well as the criteria and types of association. The last literature search was performed in June 2023. In the final study, 32 articles were included. Analysis first showed that NDDs were mainly detected through medical records screening. Second, the association of specific learning disorders and major or mild neurocognitive disorder due to Alzheimer's disease was the most investigated. Third, associations were mostly based on prevalence comparisons. Finally, 66 % of studies reported a positive association between NDDs and CBNDs. Notably, up to 67 % of positive associations were observed with atypical forms of certain CBNDs. Authors' interpretations suggest that NDDs could constitute a risk factor for CBNDs. However, the influence of NDDs on CBNDs still lacks evidence and biological support, possibly due to the heterogeneity of methods and criteria employed. Developing validated assessment tools for all NDDs and conducting cohort studies could be beneficial for research, and clinical practice. Indeed, this review also underlines the importance of adopting a life-span approach regarding CBNDs.
Collapse
Affiliation(s)
- Perrine L M Siguier
- Toulouse NeuroImaging Center, UMR1214, Toulouse University III, Inserm, CHU PURPAN - Pavillon BAUDOT, Place du Dr Joseph Baylac, 31024 TOULOUSE cedex 3, France; Laboratoire de Neuropsycholinguistique, EA4156, University of Toulouse II, 5 allée Antonio Machado, 31058 TOULOUSE cedex 9, France.
| | - Mélanie Planton
- Toulouse NeuroImaging Center, UMR1214, Toulouse University III, Inserm, CHU PURPAN - Pavillon BAUDOT, Place du Dr Joseph Baylac, 31024 TOULOUSE cedex 3, France; Department of Neurology, Neuroscience Centre, Toulouse-Purpan University Hospital, Place du Dr Baylac, TSA 40 031, 31059 Toulouse cedex 9, France
| | - Eloise Baudou
- Toulouse NeuroImaging Center, UMR1214, Toulouse University III, Inserm, CHU PURPAN - Pavillon BAUDOT, Place du Dr Joseph Baylac, 31024 TOULOUSE cedex 3, France; Neuropediatric Department, Toulouse-Purpan University Hospital, 330 avenue de Grande Bretagne - TSA 70034 - 31059 Toulouse cedex 9, France
| | - Yves Chaix
- Toulouse NeuroImaging Center, UMR1214, Toulouse University III, Inserm, CHU PURPAN - Pavillon BAUDOT, Place du Dr Joseph Baylac, 31024 TOULOUSE cedex 3, France; Neuropediatric Department, Toulouse-Purpan University Hospital, 330 avenue de Grande Bretagne - TSA 70034 - 31059 Toulouse cedex 9, France
| | - Alix Delage
- MéD@tAS Unit, Clinical Investigation Centre INSERM 1436, Department of Medical and Clinical Pharmacology, Toulouse University Hospital, 37 Allées Jules Guesde, Toulouse 31000, France
| | - Marie Rafiq
- Department of Neurology, Neuroscience Centre, Toulouse-Purpan University Hospital, Place du Dr Baylac, TSA 40 031, 31059 Toulouse cedex 9, France
| | - Marie Wolfrum
- Department of Neurology, Neuroscience Centre, Toulouse-Purpan University Hospital, Place du Dr Baylac, TSA 40 031, 31059 Toulouse cedex 9, France
| | - Fleur Gérard
- Department of Neurology, Neuroscience Centre, Toulouse-Purpan University Hospital, Place du Dr Baylac, TSA 40 031, 31059 Toulouse cedex 9, France
| | - Mélanie Jucla
- Laboratoire de Neuropsycholinguistique, EA4156, University of Toulouse II, 5 allée Antonio Machado, 31058 TOULOUSE cedex 9, France
| | - Jérémie Pariente
- Toulouse NeuroImaging Center, UMR1214, Toulouse University III, Inserm, CHU PURPAN - Pavillon BAUDOT, Place du Dr Joseph Baylac, 31024 TOULOUSE cedex 3, France
| |
Collapse
|
2
|
Sokol DK, Lahiri DK. Neurodevelopmental disorders and microcephaly: how apoptosis, the cell cycle, tau and amyloid-β precursor protein APPly. Front Mol Neurosci 2023; 16:1201723. [PMID: 37808474 PMCID: PMC10556256 DOI: 10.3389/fnmol.2023.1201723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2023] [Accepted: 08/08/2023] [Indexed: 10/10/2023] Open
Abstract
Recent studies promote new interest in the intersectionality between autism spectrum disorder (ASD) and Alzheimer's Disease. We have reported high levels of Amyloid-β Precursor Protein (APP) and secreted APP-alpha (sAPPa ) and low levels of amyloid-beta (Aβ) peptides 1-40 and 1-42 (Aβ40, Aβ42) in plasma and brain tissue from children with ASD. A higher incidence of microcephaly (head circumference less than the 3rd percentile) associates with ASD compared to head size in individuals with typical development. The role of Aβ peptides as contributors to acquired microcephaly in ASD is proposed. Aβ may lead to microcephaly via disruption of neurogenesis, elongation of the G1/S cell cycle, and arrested cell cycle promoting apoptosis. As the APP gene exists on Chromosome 21, excess Aβ peptides occur in Trisomy 21-T21 (Down's Syndrome). Microcephaly and some forms of ASD associate with T21, and therefore potential mechanisms underlying these associations will be examined in this review. Aβ peptides' role in other neurodevelopmental disorders that feature ASD and acquired microcephaly are reviewed, including dup 15q11.2-q13, Angelman and Rett syndrome.
Collapse
Affiliation(s)
- Deborah K. Sokol
- Section of Pediatrics, Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, United States
| | - Debomoy K. Lahiri
- Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, United States
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, United States
| |
Collapse
|
3
|
Klein CB, McQuaid GA, Charlton RA, Klinger LG, Wallace GL. Self-reported cognitive decline among middle and older age autistic adults. Autism Res 2023; 16:605-616. [PMID: 36513614 DOI: 10.1002/aur.2877] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2022] [Accepted: 12/04/2022] [Indexed: 12/15/2022]
Abstract
Very little is known about autistic adults as they age. Early evidence suggests a potentially high risk for dementia and atypical cognitive decline in autistic middle and older age adults. Research in the general population indicates that self-reported cognitive decline may predict future dementia earlier than performance-based measures. Nevertheless, self-report dementia screeners have not been used to date in autism research. In a sample of middle and older age autistic adults (N = 210), participants completed a self-rated dementia screener, the AD8, to describe the rate of cognitive decline, examine associations of cognitive decline with age, educational level, sex designated at birth, and autistic traits, and document the psychometrics of a dementia screener in autistic adults. We found high rates of cognitive decline with 30% of the sample screening positive. The most common symptoms were declining interest in leisure activities, and increases in everyday problems with thinking, memory, and judgment. There was evidence that autistic individuals designated female at birth may be more vulnerable to cognitive decline than autistic individuals designated male at birth. Notably, reports of cognitive decline did not vary by age or educational level. Modestly elevated autistic traits were found in those screening positive versus negative for cognitive decline. Finally, the dementia screener showed good psychometrics, including convergent validity with an independent measure of current memory problems. These results could signal an emerging public health crisis in autistic adults as they age, and support the potential utility of self-report measures for early screening for cognitive decline in this population.
Collapse
Affiliation(s)
- Claire B Klein
- Department of Psychiatry, The University of North Carolina TEACCH Autism Program, Chapel Hill, North Carolina, USA
| | - Goldie A McQuaid
- Department of Psychology, George Mason University, Fairfax, Virginia, USA
| | | | - Laura G Klinger
- Department of Psychiatry, The University of North Carolina TEACCH Autism Program, Chapel Hill, North Carolina, USA
| | - Gregory L Wallace
- Department of Speech, Language and Hearing Sciences, The George Washington University, Washington, District of Columbia, USA
| |
Collapse
|
4
|
Rhodus EK, Barber J, Kryscio RJ, Abner EL, Bahrani AA, Lewis KES, Carey B, Nelson PT, Van Eldik LJ, Jicha GA. Frontotemporal neurofibrillary tangles and cerebrovascular lesions are associated with autism spectrum behaviors in late-life dementia. J Neurol 2022; 269:5105-5113. [PMID: 35596794 PMCID: PMC9644295 DOI: 10.1007/s00415-022-11167-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 04/29/2022] [Accepted: 05/01/2022] [Indexed: 10/18/2022]
Abstract
BACKGROUND AND OBJECTIVES The pathologic substrates or neuroanatomic regions responsible for similarities in behavioral features seen in autism spectrum disorder and late-life dementia remain unknown. The present study examined the neuropathologic features of late-life dementia in research volunteers with and without antemortem behaviors characteristic of autism spectrum disorders. METHODS Antemortem cross-sectional assessment of autistic spectrum behaviors proximal to death in persons with diagnosis of mild cognitive impairment or dementia was completed using the Gilliam Autism Rating Scale, 2nd edition (GARS-2), followed by postmortem quantitative and semiquantitative neuropathologic assessment. All individuals who completed the GARS-2 prior to autopsy were included (n = 56) and we note that no participants had known diagnosis of autism spectrum disorder. The GARS-2 was used as an antemortem screening tool to stratify participants into two groups: "Autism Possible/Very Likely" or "Autism Unlikely." Data were analyzed using nonparametric statistics comparing location and scale to evaluate between-group differences in pathologic features. RESULTS Neurofibrillary tangles (NFT; p = 0.028) density and tau burden (p = 0.032) in the frontal region, the NFT density (p = 0.048) and neuritic plaque burden (p = 0.042), and the tau burden (p = 0.032) of the temporal region, were significantly different in scale between groups. For measures with significant group differences, the medians of the Autism Possible/Very Likely group were roughly equal to the 75th percentile of the Autism Unlikely group (i.e., the distributions were shifted to the right). DISCUSSION This study links behaviors characteristic of autism to increased pathologic tau burden in the frontal and temporal lobes in persons with late-life dementia. Additional studies are needed to determine causal factors and treatment options for behaviors characteristic of autism behaviors in late-life dementias.
Collapse
Affiliation(s)
- Elizabeth K Rhodus
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA.
- Department of Behavioral Science, University of Kentucky, Lexington, KY, USA.
| | - Justin Barber
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
| | - Richard J Kryscio
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
- Department of Statistics, University of Kentucky, Lexington, KY, USA
- Department of Biostatistics, University of Kentucky, Lexington, KY, USA
| | - Erin L Abner
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
- Department of Epidemiology, University of Kentucky, Lexington, KY, USA
- Department of Biostatistics, University of Kentucky, Lexington, KY, USA
| | - Ahmed A Bahrani
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
| | - Kristine E Shady Lewis
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
| | - Brandi Carey
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
| | - Peter T Nelson
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
- Department of Pathology and Division of Neuropathology, University of Kentucky, Lexington, KY, USA
| | - Linda J Van Eldik
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
- Department of Neuroscience, University of Kentucky, Lexington, KY, USA
| | - Gregory A Jicha
- Sanders-Brown Center on Aging, University of Kentucky, 1030 S. Broadway, Ste 5, Lexington, KY, 40536, USA
- Department of Behavioral Science, University of Kentucky, Lexington, KY, USA
- Department of Neurology, University of Kentucky, Lexington, KY, USA
| |
Collapse
|